| Literature DB >> 25114907 |
Zhimei Tan1, Huihua Liu2, Tiebin Yan2, Dongmei Jin2, Xiaokuo He2, Xiuyuan Zheng2, Shuwei Xu2, Chunmei Tan3.
Abstract
OBJECTIVE: To investigate the effectiveness of four-channel FES based on a normal gait pattern on improving functional ability in subjects early after ischemic stroke.Entities:
Mesh:
Year: 2014 PMID: 25114907 PMCID: PMC4119719 DOI: 10.1155/2014/545408
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flowchart of the study.
Figure 2Timing of stimulation sequence in a gait cycle.
Figure 3Treatment setting for four-channel functional electrical stimulation in side lying.
Subject characteristics.
| Four-channel | Placebo | Dual-channel | |
|---|---|---|---|
| ( | ( | ( | |
| Age (years) | 63.4 ± 10.6 | 67.0 ± 9.0 | 64.6 ± 8.3 |
| Gender (male/female) | 8/8 | 8/9 | 8/6 |
| Brunnstrom (I/II/IV) | 1/4/11 | 1/6/8 | 1/4/9 |
| Time since onset (days) | 41.3 ± 29.4 | 41.5 ± 20.4 | 41.6 ± 22.1 |
Four-channel, placebo, and dual-channel denote groups which received four-channel FES, four-channel FES placebo, and dual-channel FES, respectively. Value: mean ± SD.
Comparison of outcomes measurements among the 3 groups.
| Variable | Group | Week 0 | Week 1 | Week 2 | Week 3 | Followup |
|---|---|---|---|---|---|---|
| FMA | Four-channel | 14.5 ± 5.1 | 18.7 ± 4.9## | 20.6 ± 5.1## | 21.8 ± 4.9## | 23.3 ± 4.9 |
| Placebo | 14.8 ± 5.6 | 16.6 ± 6.2## | 17.9 ± 5.5## | 18.2 ± 5.4## | 19.5 ± 6.2 | |
| Dual-channel | 14.3 ± 5.1 | 15.9 ± 5.1# | 16.8 ± 5.5## | 17.3 ± 5.6##∗ | 19.3 ± 6.4 | |
|
| ||||||
| PASS | Four-channel | 18.9 ± 8.8 | 26.6 ± 5.5## | 28.9 ± 4.8## | 29.8 ± 4.3## | 30.9 ± 3.4 |
| Placebo | 20.4 ± 9.1 | 22.1 ± 8.9## | 23.8 ± 8.2## | 24.1 ± 8.1##∗ | 25.7 ± 8.2 | |
| Dual-channel | 19.6 ± 10.1 | 22.0 ± 9.1## | 24.5 ± 8.4## | 25.4 ± 8.6# | 26.8 ± 8.5 | |
|
| ||||||
| BBS | Four-channel | 17.2 ± 14.9 | 30.4 ± 14.9# | 37.6 ± 14.0# | 39.1 ± 13.5# | 42.7 ± 11.2 |
| Placebo | 16.5 ± 16.7 | 21.1 ± 18.0# | 24.4 ± 18.1#∗ | 25.4 ± 18.3#∗ | 29.3 ± 18.7∗ | |
| Dual-channel | 16.3 ± 16.3 | 19.5 ± 16.8# | 24.8 ± 15.6#∗ | 27.4 ± 16.1# | 31.9 ± 18.6 | |
|
| ||||||
| MBI | Four-channel | 48.9 ± 23.8 | 65.7 ± 20.3# | 76.3 ± 15.6# | 80.3 ± 16.5# | 87.4 ± 15.2 |
| Placebo | 48.5 ± 21.7 | 58.0 ± 22.3# | 64.3 ± 19.9# | 66.7 ± 19.1#∗ | 72.9 ± 21.9∗ | |
| Dual-channel | 48.1 ± 22.6 | 55.3 ± 21.8# | 62.5 ± 19.5#∗ | 64.6 ± 17.8#∗ | 75.8 ± 21.8 | |
|
| ||||||
| FAC | Four-channel | 1.1 ± 1.4 | 1.5 ± 1.4 | 2.4 ± 1.5 | 2.6 ± 1.6 | 3.5 ± 1.5 |
| Placebo | 0.8 ± 1.3 | 1.0 ± 1.4 | 1.5 ± 1.4 | 1.5 ± 1.3 | 2.3 ± 1.9 | |
| Dual-channel | 0.7 ± 1.1 | 0.8 ± 1.1 | 1.1 ± 1.1 | 1.4 ± 1.1 | 2.4 ± 1.8 | |
Value: mean ± SD. # P < 0.05, ## P < 0.01 indicate significant differences when comparing the score of all outcomes for week 1 to followup at 3 months after the 3-week treatment ended with week 0 within-group. *P < 0.05 indicates significant difference when compared with the four-channel group.
Figure 4Comparison among the 3 groups: (a) FMA score, (b) PASS score, (c) BBS score, and (d) MBI at weeks 0, 1, 2, 3, and at follow-up 3 months later. ∗indicates a difference compared with the four-channel group significant at the 5% level of confidence.